University of California

The Hospital for Sick Children

Other

Colin Conrad Collins

Joe W Gray

Johanna Rommens

Tony E Godfrey

Soo-In Hwang

David Kowbel

Daniel Pinkel

Donna G Albertson

Olli-Pekka Kallioniemi

Bauke Ylstra

Minna M Tanner

Pamela Paris

Bauke Ystra

Stanislav Volik

Dan Pinkel

Russell Baldocchi

The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.

Genes from 20q13 amplicon and their uses

This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.

Detecting CYP24 expression level as a marker for predisposition to cancer

Genes from the 20q13 amplicon and their uses

The present invention relates to cDNA sequences from a region of amplification on chromosomeassociated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.

Genes from the 20Q13 amplicon and their uses

[object Object]

The present invention provides genomic markers for determining the predisposition of prostate cancer to become metastasized.

Biomarkers for prostate cancer metastasis

The present invention provides a novel method to identify rearrangements in a test genome, e.g., a tumor genome, when compared to a reference genome. This method provides major improvements over previous methods in terms of efficiency, rapidity, and cost-effectiveness. Briefly, this method involves generating or obtaining a large insert vector library from a test genome, sequencing the ends of the inserts in the library, and comparing the co-linearity of the sequenced ends in the library with corresponding sequences within a substantially-sequenced reference genome. This invention is useful for any of a number of applications, including for identifying rearrangements in tumor genomes and for determining genetic differences between closely related species as well as between different strains of the same species.

End sequence profiling

This invention pertains to the field of cancer genetics and cytogenetics. In particular, this invention pertains to the identification of a novel amplicon on human chromosome 20 which is associated with cancer. More particularly this invention pertains to the identification of a novel &ldquo;amplicon&rdquo; or genomic nucleic acid in a region of amplification at about 20q13.2 which has been associated with a variety of cancers, particularly breast cancer. The novel amplicon of the invention can be used as a probe specific for this region of 20q13.2 as well as for the diagnosis and prognosis of various cancers. Also provided are kits for screening for the presence and copy number of the novel amplicon of the invention in a sample containing human nucleic acid.

Amplicon in the 20q13 region of human chromosome 20 and uses thereof

The present invention provides methods of determining relative copy number of target nucleic acid sequences and precise mapping of chromosomal abnormalities associated with disease. The methods of the invention use target nucleic acid sequences immobilized on a solid surface, to which a sample comprising two sets of differentially labeled nucleic acid sequences are hybridized. The hybridization of the labeled nucleic acid sequences to the solid surface is then detected using standard techniques.

Comparative fluorescence hybridization to oligonucleotide microarrays

The present invention provides methods for detecting a breast cancer based on detecting the level of any of a number of markers, wherein the level of the marker reflects the presence of breast cancer cells in a patient. This invention is based upon the surprising discovery that certain proteins that have not been previously associated with breast cancer are in fact elevated in tissues of patients with breast cancer, and thus provide methods for diagnosis of breast cancer.

Growing community of inventors

San Rafael, CA, United States of America

Colin Conrad Collins